Articles tagged with 'Export-IR' | Bayer

Newsroom Bayer (Export-IR)

2023
September
20,
2023
| 17:59 PM Europe/Amsterdam
New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds
Read more
September
19,
2023
| 08:59 AM Europe/Amsterdam
Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States. Rei...
Read more
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...
Read more
August
29,
2023
| 13:59 PM Europe/Amsterdam
New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s tes...
Read more
August
28,
2023
| 07:59 AM Europe/Amsterdam
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year. / At one-year, exploratory clinical endpoints improved overall, with...
Read more
August
24,
2023
| 10:29 AM Europe/Amsterdam
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...
Read more
August
21,
2023
| 16:44 PM Europe/Amsterdam
Leverkusen, August 21, 2023 – The Supervisory Board of Bayer AG has unanimously appointed Heike Prinz to Bayer’s Board of Management effective September 1, 2023. She will become the company’s Chief Talent Officer and Labor Director. This follows the ...
Read more
August
08,
2023
| 07:29 AM Europe/Amsterdam
Group sales fall by 8.2 percent (Fx & portfolio adj.) to 11.044 billion euros / EBITDA before special items: 2.527 billion euros (minus 24.5 percent) / Crop Science business down significantly, mainly due to sharp decline in glyphosate volumes and pr...
Read more
July
24,
2023
| 19:33 PM Europe/Amsterdam
Leverkusen, July 24, 2023 – The Bayer Group adjusted its full-year outlook for 2023 downward on Monday, mainly due to a significant further decline in sales of glyphosate-based products.For full-year 2023, Bayer now anticipates sales of between 48.5 ...
Read more
June
29,
2023
| 08:29 AM Europe/Amsterdam
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...
Read more
June
28,
2023
| 10:15 AM Europe/Amsterdam
R&D strategy poised to translate higher quality and productivity in Bayer’s innovation model into long-term growth in four key focus areas with high unmet patient needs / Shifting to breakthrough innovations based on new scientific approaches, platfo...
Read more
June
28,
2023
| 08:29 AM Europe/Amsterdam
Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year / Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment ...
Read more
June
22,
2023
| 08:29 AM Europe/Amsterdam
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...
Read more
June
20,
2023
| 13:29 PM Europe/Amsterdam
Expectation to tap into more than 100 billion euros of value in accessible and ag-adjacent markets  / Unparalleled pipeline with estimated peak sales potential of more than 30 billion euros to promote regenerative agricultural practices and enable fa...
Read more
May
23,
2023
| 19:07 PM Europe/Amsterdam
Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed
Read more
May
16,
2023
| 08:29 AM Europe/Amsterdam
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in st...
Read more
May
11,
2023
| 07:29 AM Europe/Amsterdam
Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth – headwinds...
Read more
May
03,
2023
| 14:59 PM Europe/Amsterdam
Generating 1,400 GWh annually, Idaho Renewable Energy Agreement Underscores Bayer's Global Commitment to Sustainability and Rural Communities
Read more
April
28,
2023
| 09:59 AM Europe/Amsterdam
Substantial sales and earnings growth in 2022 / Dividend of 2.40 euros per share proposed – up 20 percent / Baumann to retire at the end of May – Bill Anderson designated as his successor
Read more
March
23,
2023
| 13:59 PM Europe/Amsterdam
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...
Read more
March
21,
2023
| 10:59 AM Europe/Amsterdam
Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key con...
Read more
March
20,
2023
| 07:59 AM Europe/Amsterdam
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...
Read more
March
14,
2023
| 12:59 PM Europe/Amsterdam
Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...
Read more
March
01,
2023
| 11:59 AM Europe/Amsterdam
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...
Read more
March
01,
2023
| 07:59 AM Europe/Amsterdam
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...
Read more
February
28,
2023
| 07:30 AM Europe/Amsterdam
Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...
Read more
February
27,
2023
| 07:59 AM Europe/Amsterdam
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 
Read more
February
10,
2023
| 09:59 AM Europe/Amsterdam
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...
Read more
February
08,
2023
| 17:14 PM Europe/Amsterdam
Leverkusen, February 8, 2023 – The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimo...
Read more
February
06,
2023
| 10:59 AM Europe/Amsterdam
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...
Read more